About Us Our Focus Our Therapies
Our Pipeline Investors & News Careers

About Us

Learn about who we are, what we believe
and the people who lead us

Our Story Serving patient needs is our passion; delivering revolutionary treatments is our mission Our Leadership Our experienced leaders are bound by passion and science Our Values We live our values of commitment, empowerment and teamwork Our Responsibility Advancing a vision for change Medical Affairs We are committed to advancing science and medicine through awareness, education and research

Our Focus

Discover our unique scientific approach
for diseases with high unmet need.

Demodex Blepharitis Highly prevalent and damaging eyelid disease Lyme Disease A growing public health crisis with no approved solution Rosacea A common inflammatory skin condition

Our Therapies

The first and only FDA-approved
treatment for Demodex blepharitis

XDEMVY® (lotilaner ophthalmic solution) 0.25% Available to prescribe today

Our Pipeline

Explore the possibilities of our robust pipeline
to address significant unmet patient needs

Pipeline Overview A commitment to pursuing the root cause of disease TP-04 An investigational treatment for papulopustular rosacea TP-05 An investigational therapy for the prevention of Lyme disease

Investors & News

Find additional corporate
and stock information.

Investors Overview
News & Presentations
Events
Financials
Publications Corporate Governance
Stock Information
Other Resources

About Us

Learn about who we are, what we believe
and the people who lead us

Our Story Our Leadership Our Values Our Responsibility Medical Affairs

Our Focus

Discover our unique scientific approach
for diseases with high unmet need.
Demodex Blepharitis Lyme Disease Rosacea

Our Therapies

The first and only FDA-approved
treatment for Demodex blepharitis
XDEMVY® (lotilaner ophthalmic solution) 0.25%

Our Pipeline

Explore the possibilities of our robust pipeline
to address significant unmet patient needs
Pipeline Overview TP-04 TP-05

Investors & News

Find additional corporate
and stock information.
Investors Overview
News & Presentations
Events
Financials
Publications Corporate Governance
Stock Information
Other Resources
Careers
Pipeline Overview TP-04 TP-05

TP-05: An investigational therapeutic for the prevention of Lyme disease1

What is TP-05?

TP-05 is an oral, systemic formulation of lotilaner in development for the prevention of Lyme disease.2

What is Tarsus Pharmaceuticals

Currently, there is no FDA-approved pharmacologic option for preventing Lyme disease.2

TP-05 is1,2:

  • Believed to be the only non-vaccine, drug-based preventive therapeutic in development that targets and kills infected tick vectors before they can transmit the Borrelia bacteria that causes Lyme disease
  • An oral formulation intended to rapidly provide systemic blood levels of lotilaner, a well-characterized anti-parasitic agent, for on-demand protection
  • Currently being evaluated in a Phase 2a trial

1. Tarsus reports full-year 2022 financial results and recent business achievements. News release. Tarsus Pharmaceuticals, Inc. March 13, 2023. Accessed September 30, 2024. https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-reports-full-year-2022-financial-results-and-recent 2. Tarsus Pharmaceuticals, Inc. initiates phase 1 Callisto trial of TP-05, a novel, oral, non-vaccine therapeutic for the prevention of Lyme disease. News release. Tarsus Pharmaceuticals, Inc. June 16, 2021. Accessed September 30, 2024. https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-pharmaceuticals-inc-initiates-phase-1-callisto-trial-tp

Check out our efforts to prevent Lyme disease.

Learn more

Our Terms of Use and Privacy Policy have changed.

By clicking accept, you agree that you have read and will abide by these new terms.

Reject Accept